Several studies reported that enhancing ferroptosis through MT1G inhibitors or LCN2 antibodies increased the sensitivity of HCC to sorafenib.[60, 61] Thus, identifying new targets that enhance the therapeutic effect of sorafenib may be an effective strategy for patients with tumors. The gene discussed is MT1G; the disease is hepatocellular carcinoma.